Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Predictive value of passive tilt-induced asystole for spontaneous syncope: insights from a single-centre ILR cohort
Session:
Sessão de Posters 09 - Síncope, ILR e cardioneuromodulação
Speaker:
Patrícia Bernardes
Congress:
CPC 2026
Topic:
C. Arrhythmias and Device Therapy
Theme:
07. Syncope and Bradycardia
Subtheme:
07.3 Syncope and Bradycardia - Diagnostic Methods
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Patrícia Bernardes; Leonor Parreira; Dinis Mesquita; Jéni Quintal; Catarina Pohle; Marco Tomaz; David Campos; Sara Gonçalves; Filipe Seixo
Abstract
<p style="text-align:justify"><span style="font-size:18px"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Background</span></strong><br /> <span style="font-family:"Calibri",sans-serif">Tilt-induced asystole is considered a marker of cardioinhibitory syncope, but its predictive value for spontaneous events remains debated.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Purpose</span></strong><br /> <span style="font-family:"Calibri",sans-serif">To determine whether asystole during the passive phase of the tilt-table test (TTT) predicts spontaneous asystole documented by an implantable loop recorder (ILR), and to assess outcomes according to ILR-guided management.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Methods</span></strong><br /> <span style="font-family:"Calibri",sans-serif">This retrospective single-centre cohort (2015–2025) included adults with syncope and asystole ≥3 s occurring during the passive phase of a standard two-stage TTT protocol (70°, 20-min passive phase followed by nitroglycerin if negative). Patients whose first event occurred only after nitroglycerin were excluded. All subsequently underwent ILR implantation (median TTT-to-ILR interval 29.5 days [IQR 15.0–45.3]).</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><span style="font-family:"Calibri",sans-serif">ILR-documented symptomatic episodes were classified (blinded to TTT results) as bradycardia with asystole (pause ≥3 s), bradycardia without asystole, or normal rhythm. The primary endpoint was TTT–ILR concordance (positive predictive value, PPV). Secondary endpoints were 1-year syncope recurrence and outcomes according to therapy. Treatment was ILR-directed and included pacemaker (PM) implantation or cardioneuroablation (CNA); these were analysed as a single treated group.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:"Times New Roman",serif"><strong><span style="font-family:"Calibri",sans-serif">Results</span></strong><br /> <span style="font-family:"Calibri",sans-serif">Among 74 patients (mean age 54.7 ± 14.4 years; 58.1% women), ILR follow-up averaged 21.6 ± 7.9 months. ILR recorded ≥1 symptomatic event in 54 (73.0%). ECG-based ILR mechanisms were bradycardia with asystole 19 (25.7%), bradycardia without asystole 23 (31.1%), and normal rhythm 12 (16.2%). TTT–ILR concordance for asystole was 25.7% (19/74). Among ILR-asystolic patients, 16 were treated based on ILR findings (13 PM; 3 CNA). At 1 year, syncope recurred in 12.5% of treated patients vs 46.6% in the non-treated group (RR 0.27, 95% CI 0.07–1.01; p = 0.019); all recurrences occurred in PM recipients.</span></span></span></p> <p style="text-align:justify"><span style="font-size:18px"><span style="font-family:Aptos,sans-serif"><strong><span style="font-family:"Calibri",sans-serif">Conclusions</span></strong><br /> <span style="font-family:"Calibri",sans-serif">Passive-phase TTT asystole predicted spontaneous asystole in only one in four patients, suggesting TTT may overestimate cardioinhibition. ILR-guided therapy markedly reduces recurrence.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site